Abstract
Background: Recombinant Keratinocyte Growth Factor (rHuKGF) is a therapeutic protein used widely in oral mucositis after chemotherapy in various cancers, stimulating lung morphogenesis and gastrointestinal tract cell proliferation. In this research study, chitosan-rHuKGF polymeric complex was implemented to improve the stability of rHuKGF and used as rejuvenation therapy for the treatment of oral mucositis in cancer patients.
Objective: Complexation of rHuKGF with mucoadhesive low molecular weight chitosan to protect rHuKGF from proteolysis and investigate the effect of chitosan-rHuKGF complex on the proliferation rate of FHs 74 Int cells.
Methods: The interaction between chitosan and rHuKGF was studied by molecular docking. Malvern ZetaSizer Nano Zs and Fourier-Transform Infrared spectroscopy (FTIR) tests were carried out to characterize the chitosan-rHuKGF complex. In addition, SDS-PAGE was performed to investigate the interaction between chitosan-rHuKGF complex and pepsin. The effect of chitosan-rHuKGF complex on the proliferation rate of FHs 74 Int cells was studied by MTT assay.
Results: Chitosan-rHuKGF complex was formed through the hydrogen bonding proven by the docking studies. A stable chitosan-rHuKGF complex was formed at pH 4.5 and was protected from proteolysis and assessed by SDS PAGE. According to the MTT assay results, chitosan-rHuKGF complex increased the cell proliferation rate of FHs 74 Int cells.
Conclusion: The developed complex improved the stability and the biological function of rHuKGF.
Keywords: Chitosan, recombinant Human Keratinocyte Growth Factor (rHuKGF), complexation, proteolysis, cell proliferation, rejuvenation cancer therapy, FHs 74 Int.
Graphical Abstract
[http://dx.doi.org/10.1097/CCO.0b013e32833a9fab] [PMID: 20485169]
[http://dx.doi.org/10.1191/1078155205jp159oa] [PMID: 16390600]
[http://dx.doi.org/10.1016/S0065-230X(04)91003-2] [PMID: 15327889]
[http://dx.doi.org/10.1016/j.jtbi.2017.01.009] [PMID: 28093295]
[http://dx.doi.org/10.1093/annonc/mdl332] [PMID: 17030544]
[http://dx.doi.org/10.1016/S0925-4773(99)00325-1] [PMID: 10704888]
[http://dx.doi.org/10.1111/j.1440-1746.1996.tb00042.x] [PMID: 8985836]
[http://dx.doi.org/10.4155/tde.14.5] [PMID: 24592957]
[http://dx.doi.org/10.1517/17425247.2014.917077] [PMID: 24816134]
[http://dx.doi.org/10.1007/978-1-61779-588-6_5] [PMID: 22323219]
[http://dx.doi.org/10.1093/nar/gky427] [PMID: 29788355]
[http://dx.doi.org/10.1107/S0907444912004817] [PMID: 22525752]
[http://dx.doi.org/10.1021/ci800293n] [PMID: 19434845]
[http://dx.doi.org/10.1021/ja027200q] [PMID: 12405854]
[http://dx.doi.org/10.1074/jbc.R112.418574] [PMID: 23048026]
[http://dx.doi.org/10.1074/jbc.M116.721332] [PMID: 27405759]
[http://dx.doi.org/10.3390/polym10030267] [PMID: 30966302]
[http://dx.doi.org/10.1155/2015/821279]
[http://dx.doi.org/10.1002/jps.23225] [PMID: 22674153]
[http://dx.doi.org/10.1016/j.colsurfb.2018.05.030] [PMID: 29783151]
[http://dx.doi.org/10.1021/bm800276d] [PMID: 18540644]
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.034] [PMID: 23886649]
[http://dx.doi.org/10.1590/fst.29217]
[http://dx.doi.org/10.1590/1980-5373-mr-2018-0101]
[http://dx.doi.org/10.1016/j.molstruc.2020.128061]
[http://dx.doi.org/10.9734/IRJPAC/2016/23315]
[http://dx.doi.org/10.1021/jf204194z] [PMID: 22224939]
[http://dx.doi.org/10.1159/000243530] [PMID: 1567928]
[http://dx.doi.org/10.1186/1471-2172-10-7] [PMID: 19183498]
[http://dx.doi.org/10.2353/ajpath.2007.060935] [PMID: 17525264]
[http://dx.doi.org/10.1002/jcp.21752] [PMID: 19326389]
[http://dx.doi.org/10.1016/S0142-9612(01)00042-4] [PMID: 11575470]
[http://dx.doi.org/10.3390/polym8060214] [PMID: 30979310]
[http://dx.doi.org/10.3109/10717544.2013.819611] [PMID: 23869787]